Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 314.00
-14.00 (-4.27%)
At close: Feb 6, 2026
Stella Pharma Revenue
Stella Pharma had revenue of 108.00M JPY in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to 992.00M, up 248.07% year-over-year. In the fiscal year ending March 31, 2025, Stella Pharma had annual revenue of 961.00M with 257.25% growth.
Revenue (ttm)
992.00M
Revenue Growth
+248.07%
P/S Ratio
10.77
Revenue / Employee
23.07M
Employees
43
Market Cap
10.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 961.00M | 692.00M | 257.25% |
| Mar 31, 2024 | 269.00M | 40.00M | 17.47% |
| Mar 31, 2023 | 229.00M | 129.00M | 129.00% |
| Mar 31, 2022 | 100.00M | -105.00M | -51.22% |
| Mar 31, 2021 | 205.00M | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.61B |
| CellSource | 3.71B |
| StemCell Institute | 2.72B |
| ReproCELL | 2.63B |
| Immuno-Biological Laboratories | 1.01B |
| MEDINET | 998.00M |
| Chiome Bioscience | 727.99M |
| CellSeed | 161.00M |